Clinical studies in patients with HER2+ breast tumours demonstrated a discrepancy between BMI and clinical outcomes, including pathological response and overall survival, which may be explained by tumour heterogeneity in hormonal receptor profile, inclusion of overweight patients and intensity of anti-HER2-directed treatment within both the early and metastatic settings [68,69]. Here, ERBB2 is linked to breast neoplasm.